CCCC News and Press, C4 Therapeutics Inc.

2026-06-18 14:02:18 ET C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide June 18, 2026 9:00 AM EDT... Read the full article on Seeking Alpha For further details see: C4 Therapeutics, Inc. (CCCC...

2026-06-11 18:49:21 ET Investment Thesis This is my first time providing coverage of Monte Rosa Therapeutics, Inc. ( GLUE ), a Boston based biotech specializing in the development of a class of drugs known as molecular glue degraders ("MGDs"). As the company puts it in its Q1 20...

At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status  Cemsidomide Was Well Tolerated With Minimal Discontinuations and Dose Reductions Related to Safety or...

2026-06-02 10:58:12 ET I'm initiating C4 Therapeutics ( CCCC ) with a "Buy" rating. The reason why I'm doing so is because the company has made significant progress expanding its lead next-generation cereblon E3 ligase modulator [CELMoD] or molecular glue degrader cemsidomide ...

2026-05-29 14:27:12 ET More on Bristol-Myers Squibb Company, C4 Therapeutics Bristol-Myers Squibb Is Quietly Building Its Next Growth Cycle Bristol-Myers Squibb Company (BMY) Presents at Bank of America Global Healthcare Conference 2026 Transcript Bristol-Myers Squib...

WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences. TD Cowe...

2026-05-12 07:10:46 ET More on C4 Therapeutics C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact C4 Therapeutics, Inc. (CCCC) Presents at TD Co...

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the first quarter ended March 31, 2026, as well as rece...

2026-05-11 18:50:04 ET C4 Therapeutics, Inc. (CCCC) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 9.26%. The average open to low on the day of earnings was -6.47%. The average open to ...

2026-05-11 18:45:05 ET C4 Therapeutics, Inc. (CCCC) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in CCCC stock price following earnings has averaged ±2.80% , with a median of 1.43%. ...